Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review.

In a trial, the effect of therapeutic infliximab [ 28 ], with the dose either standard or based on drug monitoring in patients with autoimmune rheumatic diseases, including 42 patients with PsA, a slightly better therapeutic outcome with the standard dose was observed, although the difference did not reach statistical significance.

also in 111,027 other papers